Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603288 | 0.83 | SLC18A2 (0.49) | — | |
| SCHEMBL11486266 | 0.79 | CCR3 (0.42) | ALDH1A1 | |
| SCHEMBL11479223 | 0.79 | KDM4E (0.44) | HRH3ALDH1A1 | |
| SCHEMBL2603270 | 0.78 | SLC18A2 (0.50) | CHRM3 | |
| SCHEMBL13995045 | 0.78 | SLC18A2 (0.50) | CHRM3 | |
| SCHEMBL26729863 | 0.76 | CHRM3 (0.48) | CHRM3LTA4HPTGER4PTGER2ALDH1A1 | |
| SCHEMBL11372466 | 0.76 | CHI3L1 (0.43) | HRH3ALDH1A1 | |
| SCHEMBL4331452 | 0.74 | SLC18A2 (0.46) | — | |
| SCHEMBL3812261 | 0.74 | DAGLA (0.46) | KMT2ALTA4H | |
| SCHEMBL14417578 | 0.73 | HRH3 (0.49) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885KMT2A 3436/4885EPHX1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.